Autocrine stimulation of clear-cell renal carcinoma cell migration in hypoxia via HIF-independent suppression of thrombospondin-1

Scientific Reports

Volumn 2, Issue , 2012, Pages

  Bienes Martínez, Raquel ^a   Ordóñez, Angel ^a   Feijoo Cuaresma, Mónica ^a   Corral Escariz, María ^a   Mateo, Gloria ^a   Stenina, Olga ^b   Jiménez, Benilde ^c   Calzada, María J ^a  

^a AUTONOMOUS UNIVERSITY OF MADRID   (Spain)

^b LERNER RESEARCH INSTITUTE   (United States)

^c UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84869155165     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep00788     Document Type: Article

References (55)

1. Rioux-Leclercq, N. et al. Plasma level and tissue expression of vascular endothelial growth factor in renal cell carcinoma: a prospective study of 50 cases. Hum Pathol 38, 1489-1495 (2007). (Pubitemid 47418959)
2. Calzada, M. J. & del Peso, L. Hypoxia-inducible factors and cancer. Clin Transl Oncol 9, 278-289 (2007).
3. Bruick, R. K. &McKnight, S. L. A conserved family of prolyl-4-hydroxylases that modify HIF. Science 294, 1337-1340 (2001). (Pubitemid 33063099)
4. Epstein, A. C. et al. C. elegans EGL-9 andmammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation. Cell 107, 43-54 (2001). (Pubitemid 32972036)
5. Ivan, M. et al. HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing. Science. 292, 464-468 (2001). (Pubitemid 32335941)
6. Jaakkola, P. et al. Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science. 292, 468-472 (2001). (Pubitemid 32335942)
7. Mole, D. R. et al. Genome-wide association of hypoxia-inducible factor (HIF)-1alpha and HIF-2alpha DNA binding with expression profiling of hypoxiainducible transcripts. J Biol Chem 284, 16767-16775 (2009).
8. Ortiz-Barahona, A., Villar, D., Pescador, N., Amigo, J. & del Peso, L. Genomewide identification of hypoxia-inducible factor binding sites and target genes by a probabilistic model integrating transcription-profiling data and in silico binding site prediction. Nucleic Acids Res 38, 2332-2345 (2010).
9. Messmer-Blust, A., An, X. & Li, J. Hypoxia-regulated angiogenic inhibitors. Trends Cardiovasc Med 19, 252-256 (2009).
10. Good, D. J. et al. A tumour suppressor-dependent inhibitor of angiogenesis is immunologically and functionally indistinguishable from a fragment of thrombospondin. Proc Natl Acad Sci USA 87, 6624-6628 (1990).
11. Lawler, J. Thrombospondin-1 as an endogenous inhibitor of angiogenesis and tumour growth. J Cell Mol Med 6, 1-12 (2002). (Pubitemid 44133979)
12. Bornstein, P. Thrombospondins as matricellular modulators of cell function. J Clin Invest 107, 929-934 (2001). (Pubitemid 32323400)
13. Henkin, J. & Volpert, O. V. in Expert Opin Ther Targets, Vol. 15, Edn. 2011 1369-1386 (2011).
14. Castle, V., Varani, J., Fligiel, S., Prochownik, E. V. & Dixit, V. Antisense-mediated reduction in thrombospondin reverses the malignant phenotype of a human squamous carcinoma. J Clin Invest 87, 1883-1888 (1991).
15. Tuszynski, G. P., Gasic, T. B., Rothman, V. L., Knudsen, K. A. & Gasic, G. J. Thrombospondin, a potentiator of tumour cell metastasis. Cancer Res 47, 4130-4133 (1987). (Pubitemid 17108482)
16. Tuszynski, G. P., Rothman, V. L., Deutch, A. H., Hamilton, B. K. & Eyal, J. Biological activities of peptides and peptide analogues derived from common sequences present in thrombospondin, properdin, and malarial proteins. J Cell Biol 116, 209-217 (1992).
17. Adams, J. C. & Lawler, J. The thrombospondins. Int J Biochem Cell Biol. 36, 961-968 (2004). (Pubitemid 38528716)
18. Tucker, R. P. The thrombospondin type 1 repeat superfamily. Int J Biochem Cell Biol 36, 969-974 (2004). (Pubitemid 38501547)
19. Martin-Manso, G. et al. Thrombospondin 1 promotes tumour macrophage recruitment and enhances tumour cell cytotoxicity of differentiated U937 cells. Cancer Res 68, 7090-7099 (2008).
20. Isenberg, J. S. et al. Thrombospondin 1 and vasoactive agents indirectly alter tumour blood flow. Neoplasia 10, 886-896 (2008).
21. Dameron, K. M., Volpert, O. V., Tainsky, M. A. & Bouck, N. The p53 tumour suppressor gene inhibits angiogenesis by stimulating the production of thrombospondin. Cold Spring Harb Symp Quant Biol 59, 483-489 (1994).
22. Wen, S. et al. PTEN controls tumour-induced angiogenesis. Proc Natl Acad Sci USA 98, 4622-4627 (2001).
23. Janz, A., Sevignani, C., Kenyon, K., Ngo, C. V. & Thomas-Tikhonenko, A. Activation of the myc oncoprotein leads to increased turnover of thrombospondin-1 mRNA. Nucleic Acids Res 28, 2268-2275 (2000). (Pubitemid 30639360)
24. Mettouchi, A. et al. SPARC and thrombospondin genes are repressed by the c-jun oncogene in rat embryo fibroblasts. EMBO J 13, 5668-5678 (1994). (Pubitemid 24363035)
25. Slack, J. L. & Bornstein, P. Transformation by v-src causes transient induction followed by repression of mouse thrombospondin-1. Cell Growth Differ 5, 1373-1380 (1994). (Pubitemid 24381526)
26. Volpert, O. V. et al. Id1 regulates angiogenesis through transcriptional repression of thrombospondin-1. Cancer Cell. 2, 473-483 (2002). (Pubitemid 41043952)
27. Wen, X. F. et al. HER2 signalling modulates the equilibrium between pro-and antiangiogenic factors via distinct pathways: implications for HER2-targeted antibody therapy. Oncogene 25, 6986-6996 (2006).
28. Watnick, R. S., Cheng, Y. N., Rangarajan, A., Ince, T. A. & Weinberg, R. A. Ras modulates Myc activity to repress thrombospondin-1 expression and increase tumour angiogenesis. Cancer Cell 3, 219-231 (2003). (Pubitemid 37443878)
29. Li, Q., Ahuja, N., Burger, P. C. & Issa, J. P. Methylation and silencing of the Thrombospondin-1 promoter in human cancer. Oncogene 18, 3284-3289 (1999). (Pubitemid 29286973)
30. Distler, J. H. et al. Hypoxia-induced increase in the production of extracellular matrix proteins in systemic sclerosis. Arthritis Rheum 56, 4203-4215 (2007). (Pubitemid 350262349)
31. Laderoute, K. R. et al.Opposing effects of hypoxia on expression of the angiogenic inhibitor thrombospondin 1 and the angiogenic inducer vascular endothelial growth factor. Clin Cancer Res 6, 2941-2950 (2000). (Pubitemid 30482137)
32. Osada-Oka, M., Ikeda, T., Akiba, S. & Sato, T. Hypoxia stimulates the autocrine regulation of migration of vascular smooth muscle cells via HIF-1alphadependent expression of thrombospondin-1. J Cell Biochem 104, 1918-1926 (2008).
33. Park, J. E. et al. Hypoxic tumour cell modulates its microenvironment to enhance angiogenic and metastatic potential by secretion of proteins and exosomes. Mol Cell Proteomics 9, 1085-1099 (2010).
34. Phelan, M. W., Forman, L. W., Perrine, S. P. & Faller, D. V. Hypoxia increases thrombospondin-1 transcript and protein in cultured endothelial cells. J Lab Clin Med 132, 519-529 (1998). (Pubitemid 28564710)
35. Polotsky, V. Y. et al. Intermittent and Sustained Hypoxia Induce a Similar Gene Expression Profile in the Human Aortic Endothelial Cells. Physiol Genomics (2010).
36. Tenan, M. et al. Thrombospondin-1 is downregulated by anoxia and suppresses tumourigenicity of human glioblastoma cells. J Exp Med 191, 1789-1798 (2000).
37. Hu, C. J. et al. Promoter region methylation and reduced expression of thrombospondin-1 after oxygen-glucose deprivation in murine cerebral endothelial cells. J Cereb Blood Flow Metab 26, 1519-1526 (2006).
38. Zubac, D. P. et al. The expression of thrombospondin-1 and p53 in clear cell renal cell carcinoma: its relationship to angiogenesis, cell proliferation and cancer specific survival. J Urol 182, 2144-2149 (2009).
39. Veliceasa, D. et al. Transient potential receptor channel 4 controls thrombospondin-1 secretion and angiogenesis in renal cell carcinoma. FEBS J 274, 6365-6377 (2007). (Pubitemid 350215931)
40. Bussolati, B., Assenzio, B., Deregibus, M. C. & Camussi, G. The proangiogenic phenotype of human tumour-derived endothelial cells depends on thrombospondin-1 downregulation via phosphatidylinositol 3-kinase/Akt pathway. J Mol Med 84, 852-863 (2006). (Pubitemid 44477419)
41. Kwon, D. S. et al. Signal transduction of MEK/ERK and PI3K/Akt activation by hypoxia/reoxygenation in renal epithelial cells. Eur J Cell Biol 85, 1189-1199 (2006). (Pubitemid 44548871)
42. Alvarez-Tejado, M. et al. Hypoxia induces the activation of the phosphatidylinositol 3-kinase/Akt cell survival pathway in PC12 cells: protective role in apoptosis. J Biol Chem 276, 22368-22374 (2001).
43. Semenza, G. L. HIF-1, O(2), and the 3 PHDs: how animal cells signal hypoxia to the nucleus. Cell 107, 1-3 (2001). (Pubitemid 32972030)
44. Chen, K. F., Lai, Y. Y., Sun, H. S. & Tsai, S. J. Transcriptional repression of human cad gene by hypoxia inducible factor-1alpha. Nucleic Acids Res 33, 5190-5198 (2005). (Pubitemid 41487827)
45. Wen, W. et al. Suppression of cyclin D1 by hypoxia-inducible factor-1 via direct mechanism inhibits the proliferation and 5-fluorouracil-induced apoptosis of A549 cells. Cancer Res 70, 2010-2019 (2010).
46. McGray, A. J., Gingerich, T., Petrik, J. J. & Lamarre, J. Regulation of thrombospondin-1 expression through AU-rich elements in the 39UTR of the mRNA. Cell Mol Biol Lett 16, 55-68 (2011).
47. Bhattacharyya, S., Marinic, T. E., Krukovets, I., Hoppe, G. & Stenina, O. I. Cell type-specific post-transcriptional regulation of production of the potent antiangiogenic and proatherogenic protein thrombospondin-1 by high glucose. J Biol Chem 283, 5699-5707 (2008).
48. Dews, M. et al. Augmentation of tumour angiogenesis by a Myc-activated microRNA cluster. Nat Genet 38, 1060-1065 (2006). (Pubitemid 44325933)
49. Liu, L. Z. et al. MiR-21 induced angiogenesis through AKT and ERK activation and HIF-1alpha expression. PLoS One 6, e19139 (2011).
50. Polytarchou, C. et al. Akt2 regulates all Akt isoforms and promotes resistance to hypoxia through induction of miR-21 upon oxygen deprivation. Cancer Res 71, 4720-4731 (2011).
51. Niu, Q. et al. Inhibition of Tie-2 signalling induces endothelial cell apoptosis, decreases Akt signalling, and induces endothelial cell expression of the endogenous anti-angiogenic molecule, thrombospondin-1. Cancer Biol Ther 3, 402-405 (2004). (Pubitemid 41350872)
52. Chen, J. et al. Akt1 regulates pathological angiogenesis, vascular maturation and permeability in vivo. Nat Med. 11, 1188-1196 (2005). (Pubitemid 43093666)
53. Kaur, S. et al. Thrombospondin-1 inhibits VEGF receptor-2 signalling by disrupting its association with CD47. J Biol Chem 285, 38923-38932 (2010).
54. Jokilehto, T. & Jaakkola, P. M. The role of HIF prolyl hydroxylases in tumour growth. J Cell Mol Med 14, 758-770 (2010).
55. Maxwell, P. H. et al. The tumour suppressor protein VHL targets hypoxiainducible factors for oxygen-dependent proteolysis. Nature 399, 271-275 (1999). (Pubitemid 29246458)